|
| Study population | Mg supplementation | Comparator group | Duration of treatment | Clinical outcome | Year [Reference] |
|
| 24 patients with uncomplicated hypertension | 600 mg of magnesium pidolate | 24 age- and sex-matched controls | 12 weeks | Small but significant reductions in mean 24 h systolic and diastolic BP levels | 2009 [18] |
| 35 patients with essential hypertension | magnesium 70.8 mg/d; potassium 217.2 mg/d | 32 patients received lacidipine (4 mg/d) | 4 weeks | Systolic and diastolic BP decreased, and small arterial compliance values increased | 2006 [28] |
| 60 hypertensive patients | 20 mmol/d magnesium oxide | 60 hypertensive patients in a control period, crossover design | 8 weeks | Office, home, and average 24-hour BPs were significantly lower in the magnesium supplementation period | 1998 [29] |
| 15 patients with mild to moderate primary hypertension | 600 mg/day of oxide magnesium | 15 hypertensive patients in a crossover design, receiving placebo | 6 weeks | Significant reduction of systolic, diastolic, and mean BP | 1996 [19] |
| 698 healthy adults with high-normal diastolic blood pressure | 360 mg of magnesium (diglycine) | 1 g of calcium (carbonate) | 6 months | Neither calcium nor magnesium produced significant changes in BP at 3 and 6 months | 1995 [30] |
| 14 mild to moderate hypertensives | Magnesium pidolate (15 mmol/day) | Placebo | 6 months | Magnesium supplementation does not affect BP at rest and during sympathetic stimulation | 1992 [31] |
| 71 subjects with mild hypertension or a high-normal BP | 15 mmol Mg | Placebo | 6 months | No general effects on the BP | 1991 [32] |
|
